Compare JUBILANT LIFE SCIENCES with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES AUROBINDO PHARMA JUBILANT LIFE SCIENCES/
AUROBINDO PHARMA
 
P/E (TTM) x 13.6 10.5 130.3% View Chart
P/BV x 1.6 2.3 70.1% View Chart
Dividend Yield % 0.9 0.6 169.9%  

Financials

 JUBILANT LIFE SCIENCES   AUROBINDO PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
AUROBINDO PHARMA
Mar-18
JUBILANT LIFE SCIENCES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs898809 111.0%   
Low Rs618504 122.5%   
Sales per share (Unadj.) Rs572.0281.1 203.5%  
Earnings per share (Unadj.) Rs36.241.4 87.6%  
Cash flow per share (Unadj.) Rs59.550.9 117.0%  
Dividends per share (Unadj.) Rs4.502.50 180.0%  
Dividend yield (eoy) %0.60.4 155.9%  
Book value per share (Unadj.) Rs301.9199.4 151.4%  
Shares outstanding (eoy) m159.28585.88 27.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.3 56.7%   
Avg P/E ratio x20.915.9 131.8%  
P/CF ratio (eoy) x12.712.9 98.7%  
Price / Book Value ratio x2.53.3 76.2%  
Dividend payout %12.46.0 205.5%   
Avg Mkt Cap Rs m120,694384,630 31.4%   
No. of employees `0002.417.3 13.8%   
Total wages/salary Rs m19,26021,308 90.4%   
Avg. sales/employee Rs Th38,120.69,500.7 401.2%   
Avg. wages/employee Rs Th8,058.41,229.4 655.5%   
Avg. net profit/employee Rs Th2,414.31,397.9 172.7%   
INCOME DATA
Net Sales Rs m91,108164,666 55.3%  
Other income Rs m3571,020 35.0%   
Total revenues Rs m91,466165,686 55.2%   
Gross profit Rs m17,39037,718 46.1%  
Depreciation Rs m3,7095,580 66.5%   
Interest Rs m2,198777 282.8%   
Profit before tax Rs m11,84032,380 36.6%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,2688,183 39.9%   
Profit after tax Rs m5,77024,229 23.8%  
Gross profit margin %19.122.9 83.3%  
Effective tax rate %27.625.3 109.2%   
Net profit margin %6.314.7 43.0%  
BALANCE SHEET DATA
Current assets Rs m45,848121,878 37.6%   
Current liabilities Rs m20,89786,806 24.1%   
Net working cap to sales %27.421.3 128.6%  
Current ratio x2.21.4 156.3%  
Inventory Days Days57130 43.7%  
Debtors Days Days5168 74.5%  
Net fixed assets Rs m65,49881,037 80.8%   
Share capital Rs m159586 27.2%   
"Free" reserves Rs m47,930116,218 41.2%   
Net worth Rs m48,089116,804 41.2%   
Long term debt Rs m42,4294,512 940.4%   
Total assets Rs m114,685211,052 54.3%  
Interest coverage x6.442.7 15.0%   
Debt to equity ratio x0.90 2,284.0%  
Sales to assets ratio x0.80.8 101.8%   
Return on assets %6.911.8 58.6%  
Return on equity %12.020.7 57.8%  
Return on capital %12.427.4 45.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,42280,727 15.4%   
Fx outflow Rs m17,22734,700 49.6%   
Net fx Rs m-4,80546,027 -10.4%   
CASH FLOW
From Operations Rs m11,21519,548 57.4%  
From Investments Rs m-10,118-19,570 51.7%  
From Financial Activity Rs m6,5748,642 76.1%  
Net Cashflow Rs m7,6128,922 85.3%  

Share Holding

Indian Promoters % 45.6 54.1 84.3%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 8.0 109.4%  
FIIs % 21.2 27.7 76.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.2 206.9%  
Shareholders   23,815 69,601 34.2%  
Pledged promoter(s) holding % 15.9 8.6 185.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Gains 300 Points; Hero MotoCorp & Maruti Suzuki Top Gainers(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Signs of easing trade tension between the US and China provided some respite to investors globally.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Oct 15, 2019 01:53 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS